This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF
catalog :
174-TC
quantity :
50 ug
price :
339 USD
citations: 3
Reference
Mulazzani M, Huber M, Borchard S, Langer S, Angele B, Schuh E, et al. APRIL and BAFF: novel biomarkers for central nervous system lymphoma. J Hematol Oncol. 2019;12:102 pubmed publisher
Isik G, Sliepen K, van Montfort T, Sanders R. Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. PLoS ONE. 2014;9:e107683 pubmed publisher
Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103:3148-57 pubmed
product information
brand :
R&D Systems
master code :
174-TC
SKU :
174-TC-050
product name :
Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF
description :
The Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
TACI/TNFRSF13B/CVID
category :
Proteins and Enzymes
unit size :
50 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain
species :
Human
observed molecular weight :
51 kDa and 40 kDa, reducing conditions
theoretical molecular weight :
45.2 kDa (starts at Ser2, monomer)31.3 kDa (starts at Ser123, monomer)
gene symbol :
TNFRSF13B
details of functionality :
Measured by its ability to inhibit BAFF-mediated proliferation of anti-IgM stimulated mouse B cells. Moore, P.A. et al . (1999) Science 285 :260; Gross, J.A. et al . (2000) Nature 404 :995; Schneider, P. et al . (1999) J. Exp. Med. 189 :1747. The ED50 for this effect is 3-10 ng/mL.
endotoxin note :
<1.0 EU per 1 µg of the protein by the LAL method.
catalog number base :
174-TC
accessionNumbers :
Q53F36
applications :
Bioactivity
source :
Mouse myeloma cell line, NS0-derived human TACI/TNFRSF13B protein Human TACI (Ser2-Thr166) Accession # Q53F36 DIEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
2020 USD :
339
2021 USD :
339 USD
alt names :
CD267, CD267 antigen, CVID, CVID2, FLJ39942, MGC133214, TACIMGC39952, TNFRSF13B, TNFRSF14B, Transmembrane activator and CAML interactor, tumor necrosis factor receptor 13B, tumor necrosis factor receptor superfamily member 13B, tumor necrosis factor receptor superfamily, member 13B
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.